ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA
Clinical trials for ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for aggressive lymphoma: targeted drug combo shows promise
Disease control OngoingThis study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. The goal is to find the best dose and see if the combination is safe and works better than standard treatment alone. Ab…
Matched conditions: ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 10:26 UTC
-
New combo therapy shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a new drug called ALX148 combined with two standard treatments (rituximab and lenalidomide) for people with B-cell non-Hodgkin lymphoma that has not responded to prior therapy. The goal is to find the best dose and see if the combination can shrink or control the…
Matched conditions: ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:00 UTC